No profile data available.
Xencor, Inc. (XNCR) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Pasadena, United States, with about 260 full-time employees.
It reported revenue of $125.58 million for fiscal year 2025, up 13.7% from fiscal year 2024, and net income of -$91.92 million. Its market capitalization was $1.83 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.
Xencor reported $125.58 million in revenue for fiscal year 2025, up 13.7% from $110.49 million in fiscal year 2024.
$1.83 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Bausch Health Companies Inc. (BHC), Perrigo Company plc (PRGO), Intellia Therapeutics, Inc. (NTLA), ANI Pharmaceuticals, Inc. (ANIP).